tetano
Editor, Senior Moderator
J Infect Dev Ctries
. 2022 Jan 31;16(1):101-111.
doi: 10.3855/jidc.15386.
The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection
Dimitra Ioanna Lampropoulou[SUP] 1 [/SUP], Vanessa Meletia Bala[SUP] 2 [/SUP], Eleni Zerva[SUP] 2 [/SUP], Evangelia Pliakou[SUP] 2 [/SUP], Dimitrios Filippou[SUP] 3 [/SUP], Maria Gazouli[SUP] 4 [/SUP], Gerasimos Aravantinos[SUP] 2 [/SUP]
Affiliations
Abstract
Introduction: During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments.
Methodology: We reviewed recent literature (Pubmed, Google, Clinicaltrials.gov), as of the middle of May 2021, for evidence regarding the potential benefit from poly(ADP-ribose)-polymerase inhibitors and vascular endothelial growth factor blockade in severe SARS-CoV-2 infection.
Results: poly(ADP-ribose)-polymerase inhibitors have been suggested as potential agents against coronavirus disease 2019 (COVID-19) by a variety of mechanisms. vascular endothelial growth factor-associated vascular permeability is implicated with increased vascular leakage and pulmonary oedema. Thus, anti-angiogenesis factors, such as bevacizumab are being investigated in critically ill COVID-19 patients.
Conclusions: The synergistic potential of these two classes of inhibitors in severe COVID-19 management could be beneficial. Further research should be carried out in order to support this hypothesis.
Keywords: PARP-1 inhibitors; SARS-CoV-2; VEGF; bevacizumab; olaparib.
. 2022 Jan 31;16(1):101-111.
doi: 10.3855/jidc.15386.
The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection
Dimitra Ioanna Lampropoulou[SUP] 1 [/SUP], Vanessa Meletia Bala[SUP] 2 [/SUP], Eleni Zerva[SUP] 2 [/SUP], Evangelia Pliakou[SUP] 2 [/SUP], Dimitrios Filippou[SUP] 3 [/SUP], Maria Gazouli[SUP] 4 [/SUP], Gerasimos Aravantinos[SUP] 2 [/SUP]
Affiliations
- PMID: 35192527
- DOI: 10.3855/jidc.15386
Abstract
Introduction: During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments.
Methodology: We reviewed recent literature (Pubmed, Google, Clinicaltrials.gov), as of the middle of May 2021, for evidence regarding the potential benefit from poly(ADP-ribose)-polymerase inhibitors and vascular endothelial growth factor blockade in severe SARS-CoV-2 infection.
Results: poly(ADP-ribose)-polymerase inhibitors have been suggested as potential agents against coronavirus disease 2019 (COVID-19) by a variety of mechanisms. vascular endothelial growth factor-associated vascular permeability is implicated with increased vascular leakage and pulmonary oedema. Thus, anti-angiogenesis factors, such as bevacizumab are being investigated in critically ill COVID-19 patients.
Conclusions: The synergistic potential of these two classes of inhibitors in severe COVID-19 management could be beneficial. Further research should be carried out in order to support this hypothesis.
Keywords: PARP-1 inhibitors; SARS-CoV-2; VEGF; bevacizumab; olaparib.